Strategic Initiative

Slingshot members are tracking this corporate initiative:

Seattle Genetics (SGEN) and Immunomedics (IMMU) Announce $2B License Deal for IMMU-132 in Triple-Negative Breast Cancer

Source Link:: http://www.prnewswire.com/news-releases/immunomedics-enters-into-exclusive-global-licensing-agreement-with-seattle-genetics-for-sacituzumab-govitecan-immu-132-with-potential-payments-of-up-to-approximately-2-billion-plus-royalties-300405551.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

100%

100%

Strategic Initiative Date

Announcement Date:

Feb 10, 2017

Projected Implementation:

Q1, 2017

Relevance Tracked Until:

Q1, 2019

Related Projects

Related Keywords Immu-132, Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer